Health Canada approves Ipsen’s Somatuline® Autogel® for the treatment of carcinoid syndrome in adult patients with neuroendocrine tumours (NETs)

//Health Canada approves Ipsen’s Somatuline® Autogel® for the treatment of carcinoid syndrome in adult patients with neuroendocrine tumours (NETs)

Health Canada approves Ipsen’s Somatuline® Autogel® for the treatment of carcinoid syndrome in adult patients with neuroendocrine tumours (NETs)

Somatuline Autogel is the first and only somatostatin analog (SSA) approved in Canada to treat enteropancreatic neuroendocrine tumours and carcinoid syndrome.

Februaury 13th, 2018 – Health Canada announced the approval for Somatuline® Autogel® (lanreotide injection) 120 mg for the treatment of carcinoid syndrome; when used, Somatuline Autogel reduces the administrative frequency of short-acting somatostatin analog rescue therapy.

Somatuline Autogel is also approved for the treatment of enteropancreatic neuroendocrine tumours in adult patients with Grade 1 or a subset of Grade 2 (equivalent to Ki67<10%) unresectable, locally advanced or metastatic disease, to delay progression.

PRESS RELEASE: CLICK HERE

By | 2018-05-07T18:28:10+00:00 February 13th, 2018|Treatment News|0 Comments

About the Author:

Leave A Comment